EB 03

Drug Profile

EB 03

Alternative Names: EB-03

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Edesa Biotech
  • Class Antihaemorrhagics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemorrhoids
  • Discontinued Fissure in ano

Most Recent Events

  • 22 Sep 2017 EB-03 licensed to Pendopharm in Canada
  • 03 Oct 2016 Discontinued - Phase-I for Fissure in ano in Canada (Topical)
  • 03 Oct 2016 Preclinical trials in Haemorrhoids in Canada (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top